Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial
Under a Creative Commons license
open access
Keywords
Antibody persistence
Meningococcal B vaccine
Infants
Children
Booster response
2 + 1 schedule
Safety
Open-label randomised clinical trial
Abbreviations
AE
adverse event
CI
confidence interval
FAS
full analysis set
fHbp
factor H-binding protein
GMT
geometric mean titre
hSBA
serum bactericidal activity assay using human complement
IMD
invasive meningococcal disease
MenACWY-CRM
quadrivalent serogroups A, C, W and Y conjugated to the diphtheria toxin mutant CRM197
MenB
meningococcal serogroup B
4CMenB
meningococcal serogroup B vaccine
NadA
Neisserial adhesin A
NHBA
neisserial heparin-binding antigen
PorA
porin A protein
rLP2086
multicomponent vaccine against serogroup B
SAE
serious adverse event
UK
United Kingdom
Cited by (0)
Clinical Trial Registration: NCT01894919.
© 2017 GlaxoSmithKline SA. Published by Elsevier Ltd on behalf of The British Infection Association.